AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
January 24 2023 - 7:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management, and post-operative pain
management, today announced that it will release its fourth quarter
and full year 2022 financial results on Tuesday, February 21,
2023.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on
Tuesday, February 21, 2023, to discuss its fourth quarter and full
year 2022 financial results. Those interested in listening to the
conference call should register online using this link.
Participants are encouraged to register more than 15 minutes before
the start of the call. A live and replay version of the audio
webcast will be available at
https://ir.atricure.com/events-and-presentations/events.
AtriCure’s management is also scheduled to host investor
meetings at the 2023 BTIG MedTech, Digital Health, Life Science
& Diagnostic Tools Conference on Tuesday, February 14, 2023, in
Snowbird, Utah.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 37
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230124005103/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Lynn Lewis or Marissa Bych Gilmartin Group Investor Relations
lynn@gilmartinir.com marissa@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Dec 2024 to Jan 2025
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Jan 2024 to Jan 2025
